KNSA Kiniksa Pharmaceuticals Ltd: Rasio rega marang prakiraan pendapatan

Logo perusahaan publik Kiniksa Pharmaceuticals (KNSA)

The strategic goal of Kiniksa Pharmaceuticals (KNSA) is to dominate the treatment of recurrent pericarditis through its monopoly drug ARCALYST. The forward price-to-sales ratio on the GURU.Markets chart illustrates the path toward this objective, where 5.60 represents the current level of the metric. High pricing for orphan therapy and patent protection create market barriers, while growth relies solely on the licensing of new molecules.

Kiniksa - Rasio kapitalisasi marang dodolan sing dikarepake KNSA (periode 04.07.2022 - 15.11.2026)

Rincian analitis perusahaan Kiniksa Pharmaceuticals

- rega saiki lan proyeksi nilai saham:
- data kapitalisasi saham perusahaan:
Analisis fundamental perusahaan:KNSA (Kiniksa Corp)
Sampel barang Kiniksa Pharmaceuticals

Forward P/S assesses the market value of a business relative to expected revenue, allowing an investor to determine the extent of overpayment for future cash flows amid volatility. By analyzing the projected P/S ratio, one can evaluate whether the antibody patent protection of Kiniksa Pharmaceuticals (KNSA) and its monopoly status in biotechnology justify the current capitalization, confirming the company's fundamental stability.

Analisis perusahaan pesaing

Multiplikator Forward P/S ARGX (argenx.com)|BioNTech Group (BNTX) - Rasio kapitalisasi pasar marang pendapatan mangsa ngarep|ABIVAX - Multiplikator Forward P/S|ADMA - Multiplikator Forward P/S|Protagonist (PTGX) - Rasio rega marang prakiraan pendapatan|Multiplikator forward rega marang pendapatan Immunovant Inc|GRFS (Grifols Biemat) - Multiplikator Forward P/S|Multiplikator Forward P/S Adaptive Biotechnologies Inc.|Rasio rega marang prakiraan pendapatan Celldex Therapeutics (CLDX)|Rasio kapitalisasi marang dodolan sing dikarepake auriniapharma.com|Rasio rega marang prakiraan pendapatan BioCryst Pharmaceuticals BCRX|Rega forward marang dodolan VERA|Dianthus Pharma - Multiplikator Forward P/S|PHVS - Multiplikator Forward P/S|ABCL: Multiplikator Forward P/S|TRML (Tourmaline Bio, Inc.) - Rasio rega marang prakiraan pendapatan|Rasio rega marang prakiraan pendapatan Intrexon|PHAR - Prakiraan rega marang pendapatan|Multiplikator Forward P/S NKTR|Rasio rega marang prakiraan pendapatan UPB (Upstream Bio Corp)|Rasio rega marang prakiraan pendapatan Zenas Biopharma, Inc. ZBIO|Rasio kapitalisasi marang dodolan sing dikarepake immunome.com (IMNM)|Gossamer Bio Inc - Multiplikator Forward P/S|Rega forward marang dodolan KALV (KalVista Pharmaceuticals, Inc.)|SEPN: Multiplikator Forward P/S|Multiplikator forward rega marang pendapatan Pieris Pharmaceuticals Inc|Multiplikator forward rega marang pendapatan SVRA|Multiplikator forward rega marang pendapatan Rigel Pharmaceuticals (RIGL)|Multiplikator Forward P/S ANAB|ATXS - Rasio kapitalisasi pasar marang pendapatan mangsa ngarep|Rasio rega marang prakiraan pendapatan enGene Corp ENGN|Rasio kapitalisasi marang dodolan sing dikarepake RAPT Therapeutics, Inc. (RAPT)|Aerovate - Multiplikator Forward P/S|ACRS - Multiplikator Forward P/S|KYTX (Kyverna Therapeutics) - Multiplikator forward rega marang pendapatan|Rasio kapitalisasi pasar marang pendapatan mangsa ngarep Tiziana Life Sciences Ltd. (TLSA)|Multiplikator forward rega marang pendapatan CABA|Ventyx Biosciences (VTYX) - Rasio kapitalisasi marang dodolan sing dikarepake|Multiplikator Forward P/S THTX|AVTX (Avalo Therapeutics, Inc) - Rega forward marang dodolan|Multiplikator Forward P/S ELDN (eledon.com)|AGEN - Multiplikator forward rega marang pendapatan|CLYM - Rasio rega marang prakiraan pendapatan|Rega mangsa ngarep marang pendapatan ZURA|ATYR: Multiplikator Forward P/S|Adagene Corp (ADAG) - Multiplikator Forward P/S|Multiplikator forward rega marang pendapatan IMA|Shattuck Labs, Inc. - Rega mangsa ngarep marang pendapatan|Rasio rega marang prakiraan pendapatan Equillium Inc (EQ)|Multiplikator Forward P/S Connect Biopharma Holdings (CNTB)|Rasio rega marang prakiraan pendapatan Immunic, Inc. IMUX|Multiplikator Forward P/S Atara Biotherapeutics ATRA|IFRX - Rasio rega marang prakiraan pendapatan|XFOR: Rasio rega marang prakiraan pendapatan|ACET: Multiplikator Forward P/S|CELU - Rasio kapitalisasi marang dodolan sing dikarepake|Rasio rega marang prakiraan pendapatan inmunebio.com|Kapitalisasi marang prakiraan pendapatan BRNS (barinthusbio.com)|Multiplikator Forward P/S KZR|Multiplikator Forward P/S SAB Biotherapeutics, Inc (SABS)|Multiplikator Forward P/S AKTX (Akari Therapeutics, Plc)|Multiplikator Forward P/S enlivex.com ENLV|QTTB: Multiplikator forward rega marang pendapatan|GOVX - Multiplikator Forward P/S|Edesa Biotech Inc (EDSA) - Rasio rega marang prakiraan pendapatan|IBIO - Rasio kapitalisasi marang dodolan sing dikarepake|Rasio rega marang prakiraan pendapatan carismatx.com|XTLB: Rega forward marang dodolan|Rasio rega marang prakiraan pendapatan Bolt Biotherapeutics Inc. (BOLT)|HCW Biologics - Kapitalisasi marang prakiraan pendapatan|Rasio rega marang prakiraan pendapatan aptevotherapeutics.com APVO|AIM - Multiplikator forward rega marang pendapatan|Aditxt - Multiplikator Forward P/S|Rasio kapitalisasi marang dodolan sing dikarepake GRI Bio Corporation GRI|xortx.com (XRTX) - Rasio rega marang prakiraan pendapatan|Rasio kapitalisasi pasar marang pendapatan mangsa ngarep reshapelifesciences.com (HIND)|Rasio rega marang prakiraan pendapatan Revelation Bio|Rasio kapitalisasi pasar marang pendapatan mangsa ngarep Indaptus Therapeutics, Inc. INDP|Rasio rega marang prakiraan pendapatan BiondVax Pharmaceuticals (SCNI)|Multiplikator forward rega marang pendapatan CalciMedica CALI|Rasio rega marang prakiraan pendapatan Affimed AFMD|ALLK - Multiplikator forward rega marang pendapatan|HOOKIPA Pharma, Inc. - Multiplikator Forward P/S|Rega forward marang dodolan IGMS (igmbio.com)|ITOS (iTeos Therapeutics, Inc.) - Multiplikator forward rega marang pendapatan|Ocean Biomedical Corp (OCEA) - Multiplikator Forward P/S|Rasio rega marang prakiraan pendapatan TC BioPharm (Holdings) PLC|Multiplikator Forward P/S thirdharmonicbio.com